Immuno - Oncology Overview

Authors: Colin White, Robert Jeng & Jolene Lau
This is an overview of the field of immuno-oncology and the various immuno-oncology classes.

Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions. To be able to compete successfully and competitively in this market, this report is vital to add to your arsenal.

Table of Contents:
- Immuno-oncology overview
- Interviews
- CTLA-4
- PD-1/PD-L1
- TIM3
- LAG3
- OX40
- CD40
- CAR-T cell therapy
- T-cell receptor gene therapy
- Dendritic cell therapy
- CSF1R
- IDO
- CEA

Meet the Authors:

Colin White:
Lead oncology analyst at Datamonitor Healthcare
E-mail: cwhite@datamonitor.com
Follow on Twitter: @Datamonitor_CW

Robert Jeng:
Senior scientific analyst at BioMedTracker
E-mail: rjeng@sagientresearch.com
Follow on Twitter: @BMTRobert

Jolene Lau:
Scientific analyst at BioMedTracker
E-mail: jlau@sagientresearch.com
Follow on Twitter: @BMTJolene

www.datamonitorhealthcare.com
What’s included in this report?

- Three fully transcribed key opinion leader interviews
- Coverage of the key immuno-oncology targets include key clinical trial results and a summary of deals related to that class
- 10-year sales forecasts are included for Yervoy, Opdivo, Keytruda, MEDI4736, and RG7446
- Development focus map shows which targets are being investigated by each of the 63 companies with immuno-oncology drugs in development.

We’ll answer these key questions:

- What are the key immuno-oncology products in development?
- What important clinical trial results have been reported for drugs in each immuno-oncology drug class?
- What specific targets and therapy approaches are the developers in this field focusing on?
- What factors could limit the commercial potential of immuno-oncology drugs in development?
- What recent deals have taken place that are related to the field of immuno-oncology?

Highlights:

- Datamonitor Healthcare anticipates that the PD-1/PD-L1 class will gain approvals for multiple tumor types and that this class will be the most commercially successful immuno-oncology class. As monotherapies, PD-1 inhibitors are likely to gain further approvals for a wide variety of cancers.
- CAR-T cell therapy early clinical results are extremely promising. The leading CD19-targeted CAR-T treatments by Novartis, Juno, and Kite all provide response rates hovering around 90% for patients with multiply relapsed or refractory acute lymphocytic leukemia.
- In theory, a treatment cancer vaccine should be able to strengthen the immune response against a cancer. However, a series of Phase III studies investigating cancer vaccines have failed to meet their primary endpoint and the potential future role of this class has diminished with each trial failure.

Want this report?

You can purchase this report either by credit card or invoice by CLICKING HERE. If you’d rather speak to someone first, just email our team at customerservices@datamonitorhealthcare.com.

If you want to know more about Datamonitor Healthcare CLICK HERE to download our brochure.

www.datamonitorhealthcare.com
The best coverage.
The best forecasts.
The best analysts.
The best support.
The Best of Health.

We’ve just made strategic investments in Datamonitor Healthcare to give you the best of health.

Introducing The New Datamonitor Healthcare.

We’ve quadrupled our business intelligence which covers more than 90% of prescription medicines in the major markets. Our forecasts are tailored to your needs as events occur and are powered by a new forecasting tool built in collaboration with a leading analytics technology provider. We’ve increased our global analyst resources by 300%, and Live Support replies to your queries in real time, not hours, for the fastest support in the market.

Discover the best of health.
Visit www.BestofHealthDatamonitor.com to tour the new Datamonitor Healthcare with one of our representatives. Request a live demo and see how The Best of Health supports smarter, faster decision-making.